PTGX Stock Analysis: Buy, Sell, or Hold?
PTGX - Protagonist Therapeutics, Inc
$136.64
-2.00 (-1.44%)
▼
5d:
+0.39%
30d:
+9.16%
90d:
+38.06%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
2d
Get Alerted When PTGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PTGX shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: PTGX shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: PTGX is currently trading at $136.64, which is considered slightly high relative to its 30-day fair value range of $126.52 to $138.59. From a valuation perspective, the stock is trading at a discount (Forward PE: -725.3) compared to its historical average (83.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PTGX is in a strong uptrend. Immediate support is located at $130.63, while resistance sits at $143.29.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PTGX is in a strong uptrend. Immediate support is located at $130.63, while resistance sits at $143.29.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$126.52 -
$138.59
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
71.9%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($133.31)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$126.52 -
$138.59
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$9.67
(7.1%)
Support & Resistance Levels
Support Level
$130.63
Resistance Level
$143.29
Current Trend
Strong Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-725.27
Wall Street Target
$133.31
(-2.4%)
Revenue Growth (YoY)
99.0%
Earnings Growth (YoY)
351.3%
Profit Margin
-154.9%
PE vs Historical
-725.3 vs 83.6
CHEAP
Share & Embed Analysis
Last updated: August 02, 2026 6:18 PM ET
Data refreshes hourly during market hours. Next update: 7:18 PM
Data refreshes hourly during market hours. Next update: 7:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PTGX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Asif Ali
SELL
1750 shares
2026-04-20
Arturo Md Molina
SELL
15000 shares
2026-03-26
Asif Ali
SELL
24765 shares
2026-03-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 49 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 57 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 54 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 59 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
Advanced PTGX Option Strategies
Professional options setups generated by AI based on today's PTGX price and gamma walls.
